We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Vogelxo(R) ABPM Study in Hypogandal Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04558567
Recruitment Status : Recruiting
First Posted : September 22, 2020
Last Update Posted : October 19, 2022
Information provided by (Responsible Party):
Upsher-Smith Laboratories

Brief Summary:
A Phase 4 ABPM study in Hypogonadal Men

Condition or disease Intervention/treatment Phase
Hypogonadism, Male Drug: Vogelxo Phase 4

Detailed Description:
A single-arm, open-label, uncontrolled study consisting of a 4-week screening phase, 4-week titration phase, and 16-week treatment phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Phase 4, Open-Label, Single-Arm Study to Evaluate the Effects of Vogelxo(R) on 24-hour Ambulatory Blood Pressure Monitoring in Hypogonadal Men Using Therapeutic Testosterone Replacement Therapy
Actual Study Start Date : August 28, 2020
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : June 2023

Arm Intervention/treatment
Open-Label Drug: Vogelxo
50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)

Primary Outcome Measures :
  1. Change from baseline in the 24-hour ABPM average SBP [ Time Frame: 20 weeks ]
    Average SBP will be calculated from ABPM measurements taken twice each hour over the 24-hour period. An ABPM measurement session will be standardized and performed during on-site clinic visits at baseline (before treatment) and on the last day of treatment (week 20) to minimize subject variability.

Secondary Outcome Measures :
  1. Change from baseline in 24-hour average diastolic blood pressure (DBP) [ Time Frame: 20 weeks ]
  2. Change from baseline in 24-hour average heart rate (HR) [ Time Frame: 20 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adult male whose age is between 18 and 80 years, inclusive, at the time of screening.
  2. Considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at screening.
  3. Meets the study definition of clinical hypogonadism, as evidenced by serum testosterone concentrations:

    1. Two serum testosterone concentrations < 300 ng/dL collected in the morning (between 0630 hours and 1000 hours local time) on at least 2 days separated by a minimum of 48 hours.
    2. Presence of at least 1 sign or symptom that may be related to low testosterone values and is/are consistent with hypogonadism
  4. Naïve to testosterone replacement, clomiphene, compounded or over-the-counter androgenic steroid derivatives and dehydroepiandrosterone, including investigational products that may affect the reproductive hormonal system within the past 2 months.
  5. Willingness and the ability to apply topical testosterone gel as instructed by the study staff and comply with the requirements of this study protocol.
  6. Intact skin surfaces on the upper arms and shoulders where the topical testosterone will be applied.

Exclusion Criteria:

  1. Two testosterone concentrations < 100 ng/dL during screening.
  2. Prolactin concentration > 1 x upper limit of normal (ULN).
  3. Current or recurrent ulcer, erosion, lichenification, inflammation psoriasis, eczema or use of topical corticosteroids on the upper arms and shoulders. Tattoo application or removal in the region of study drug application.
  4. Known skin intolerance to alcohol or allergy to any of the ingredients of the study drug.
  5. History of treatment with growth hormone, anti-estrogen or estrogen treatment within 90 days prior to screening.
  6. Currently taking glucocorticoids > 7.5 mg prednisone equivalent per day (eg, hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) for 1 week before SV1 and through Day 1, and any use of opioids within 5 half-lives prior to Day 1.
  7. Currently taking, unstable doses within 14 days prior to first administration of study drug or anticipated to receive any antihypertensive medications, over-the-counter medications, supplements or herbal medicines known to affect blood pressure during study participation. These medications or supplements include diet pills (eg, phenylpropanolamine, sibutramine), nasal decongestants (eg, phenylephrine hydrochloride, pseudoephedrine, naphazoline hydrochloride), certain stimulants (eg, amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine), monoamine oxidase inhibitors (MAO), atypical antipsychotics (eg, clozapine, olanzapine).
  8. History of prostate (current or in the past) or breast cancer.
  9. Severe lower urinary tract symptoms as indicated by an International Prostate Symptom Score (I-PSS) > 19.
  10. Prostate-specific antigen (PSA) > 3.0 ng/mL; men treated with 5-alpha reductase inhibitors (eg, dutasteride, finasteride) are eligible for participation as long as PSA levels are not > 1.5 ng/mL.
  11. Body mass index > 50 kg/m2.
  12. Sitting SBP < 80 mm Hg and > 150 mm Hg or sitting DBP < 50 mm Hg and > 100 mm Hg at any point during screening.
  13. HbA1c > 11% at screening.
  14. A current condition, therapy, laboratory abnormality, history of clinically significant medical or psychiatric conditions or other circumstance or reasons which, in the opinion of the investigator or the study staff, might pose a risk to the subject, make participation not in the subject's best interest, confound the results of the study (eg, if subject cannot comply with requirements of the study), make the subject an unsuitable candidate to receive study drug, or interfere with the subject's participation for the full duration of the study.
  15. History, suspicion, or evidence of significant drug or alcohol abuse or illicit steroid use within the previous 12 months prior to screening, as determined by the investigator.
  16. The subject is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
  17. Clinical laboratory analysis shows any of the following abnormal results:

    • Hematocrit > 50%
    • Alanine aminotransferase or aspartate aminotransferase > 3 × ULN
  18. Severe or end-stage chronic kidney disease documented by eGFR < 30 mL/min.
  19. Subject works night shifts.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04558567

Layout table for location contacts
Contact: Medical Information 1-888-650-3789 uslinfo@upsher-smith.com

Layout table for location information
United States, Alabama
Upsher-Smith Clinical Trial Site #6 Recruiting
Birmingham, Alabama, United States, 35235
United States, California
Upsher-Smith Clinical Trial Site #2 Active, not recruiting
Anaheim, California, United States, 92801
United States, Florida
Upsher-Smith Clinical Trial Site #1 Active, not recruiting
Miami, Florida, United States, 33143
Upsher-Smith Clinical Trials Site #3 Withdrawn
Orlando, Florida, United States, 32809
United States, New York
Upsher-Smith Clinical Trials Site #7 Recruiting
Garden City, New York, United States, 11530
United States, South Carolina
Upsher-Smith Clinical Trials Site #4 Recruiting
North Charleston, South Carolina, United States, 29405
United States, Texas
Upsher-Smith Clinical Trials Site #5 Recruiting
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Upsher-Smith Laboratories
Layout table for additonal information
Responsible Party: Upsher-Smith Laboratories
ClinicalTrials.gov Identifier: NCT04558567    
Other Study ID Numbers: P361-502
First Posted: September 22, 2020    Key Record Dates
Last Update Posted: October 19, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonadal Disorders
Endocrine System Diseases